The addition of oxaliplatin increases pathological complete response: a meta-analysis of randomized controlled trials on radiochemotherapy in recta...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter L. Wyrwicz
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors L. Wyrwicz, M. Temnyk, M. Spalek
  • M Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland, /

Abstract

The standard treatment of locally advanced rectal cancer consists of neoadjuvant radio- or radiochemotherapy followed by total mesorectal excision. The optimal treatment strategy for patients who do not accept stoma or are not suitable for rectal surgery has not been yet established. Usually, the standard radiochemotherapy with 5-fluorouracil or capecitabine plus watch-and-wait strategy is suggested. There are ongoing prospective studies to confirm long-term outcomes of this approach worldwide. The question is if the addition of oxaliplatin can result in higher incidence of pathological complete response (pCR) in rectal cancer patients.